Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery.
PEG-PCL-PEG (PECE) hydrogel for intracameral injection as a sustained delivery system can get a stable release of the medication and achieve an effective local concentration. The injectable PECE hydrogel is thermosensitive nano-material which is flowing sol at low temperature and can shift to nonflowing gel at body temperature. This study evaluated the intracameral injection of bevacizumab combined with a PECE hydrogel drug release system on postoperative scarring and bleb survival after experimental glaucoma filtration surgery. The best result was achieved in the bevacizumab loaded PECE hydrogels group, which presented the lowest IOP values after surgery. And the blebs were significantly more persistent in this group. Histology, Massion trichrome staining and immunohistochemistry further demonstrated that glaucoma filtration surgery in combination with bevacizumab loaded PECE hydrogel resulted in good bleb survival due to scar formation inhibition. In conclusions, this study demonstrated that bevacizumab-loaded PECE hydrogel for intracameral injection as a sustained delivery system provide a great opportunity to increase the therapeutic efficacy of glaucoma filtration surgery.
Department of Ophthalmology, Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, China.
Qian
Q
Han
Yuqi
Y
Wang
Xiabin
X
Li
Ribo
R
Peng
Ailing
A
Li
Zhiyong
Z
Qian
Ling
L
Yu
D000199:Actins / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000068258:Bevacizumab / Q000008:administration & dosage*; D002921:Cicatrix / Q000517:prevention & control; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D018463:Filtering Surgery / Q000009:adverse effects; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D020100:Hydrogels; D007429:Intraocular Pressure / Q000187:drug effects*; D011091:Polyesters; D011092:Polyethylene Glycols; D011183:Postoperative Complications / Q000517:prevention & control; D011817:Rabbits; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000199:Actins; D020533:Angiogenesis Inhibitors; D020100:Hydrogels; D011091:Polyesters; D042461:Vascular Endothelial Growth Factor A; C502908:poly(ethylene glycol)-poly(caprolactone)-poly(ethylene glycol); D000068258:Bevacizumab; D011092:Polyethylene Glycols